PID1 (NYGGF4), a new growth-inhibitory gene in embryonal brain tumors and gliomas

scientific article published on 03 December 2013

PID1 (NYGGF4), a new growth-inhibitory gene in embryonal brain tumors and gliomas is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1158/1078-0432.CCR-13-2053
P8608Fatcat IDrelease_4ksihd67vjdmfoxwkh2tkw5tme
P932PMC publication ID3962776
P698PubMed publication ID24300787
P5875ResearchGate publication ID259154017

P50authorStefan M. PfisterQ39183179
Anat Erdreich-EpsteinQ46308678
Ashley MargolQ56334548
David T. W. JonesQ58388511
Floyd GillesQ88404064
Alexander JudkinsQ88427997
Tom DavidsonQ89355299
Marcel KoolQ90637389
P2093author name stringShahab Asgharzadeh
Hong Zhou
Mark D Krieger
Lingyun Ji
Richard Sposto
Jingying Xu
Gregory M Shackleford
Jemily Malvar
Mathew Schur
Nathan Robison
Xiuhai Ren
P2860cites workIdentification and characterization of NYGGF4, a novel gene containing a phosphotyrosine-binding (PTB) domain that stimulates 3T3-L1 preadipocytes proliferationQ24295220
Overexpression of NYGGF4 (PID1) induces mitochondrial impairment in 3T3-L1 adipocytesQ24299984
Over-expression of NYGGF4 inhibits glucose transport in 3T3-L1 adipocytes via attenuated phosphorylation of IRS-1 and AktQ24329181
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in CancerQ24608391
Molecular subgroups of medulloblastoma: the current consensusQ24615271
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1Q24651548
Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysQ24656128
Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumorsQ28294240
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcomeQ28298987
Extensive proteomic screening identifies the obesity-related NYGGF4 protein as a novel LRP1-interactor, showing reduced expression in early Alzheimer's diseaseQ28588684
Effects of NYGGF4 knockdown on insulin sensitivity and mitochondrial function in 3T3-L1 adipocytesQ28594863
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological featuresQ33366431
Use of the viral 2A peptide for bicistronic expression in transgenic miceQ33369539
Pid1 induces insulin resistance in both human and mouse skeletal muscle during obesityQ33633052
Modeling initiation of Ewing sarcoma in human neural crest cellsQ33894979
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomasQ34167499
c-Abl is an upstream regulator of acid sphingomyelinase in apoptosis induced by inhibition of integrins αvβ3 and αvβ5.Q34374088
Identification of the ligands of protein interaction domains through a functional approach.Q34584256
Insulin-like growth factor II is involved in the proliferation control of medulloblastoma and its cerebellar precursor cellsQ34650409
Novel cell lines established from pediatric brain tumors.Q36047046
Novel mutations target distinct subgroups of medulloblastoma.Q36143877
Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis.Q36411906
Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastomaQ36910335
Medulloblastoma comprises four distinct molecular variantsQ36920479
Insulin-like growth factor 2 is required for progression to advanced medulloblastoma in patched1 heterozygous miceQ37002716
Rembrandt: helping personalized medicine become a reality through integrative translational researchQ37103992
Management of and prognosis with medulloblastoma: therapy at a crossroadsQ37322966
Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivoQ40146305
Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterationsQ40339027
Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in miceQ40545772
Growth hormone and insulin-like growth factor-I: effects on the growth of glioma cell linesQ40790050
siRNA Selection Server: an automated siRNA oligonucleotide prediction serverQ41010535
Overexpression of TFAM protects 3T3-L1 adipocytes from NYGGF4 (PID1) overexpression-induced insulin resistance and mitochondrial dysfunctionQ42827369
Knockdown of NYGGF4 (PID1) rescues insulin resistance and mitochondrial dysfunction induced by FCCP in 3T3-L1 adipocytesQ42829463
Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristicsQ43631246
Glioblastoma survival in the United States before and during the temozolomide era.Q44016219
Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumorsQ44214973
Expression of two types of receptor for insulin-like growth factors in human malignant glioma.Q48107992
Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshopQ48531886
Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cellsQ54648645
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.Q55469539
Insulin-like growth factor I receptor activity in human medulloblastomas.Q55473436
Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas.Q55474277
Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma.Q55475439
Over-expression of NYGGF4 (PID1) inhibits glucose transport in skeletal myotubes by blocking the IRS1/PI3K/AKT insulin pathwayQ83031959
P4510describes a project that usesCHLA-01-MEDQ54812135
CHLA-01R-MEDQ54812137
CHLA-05-ATRTQ54812145
CHLA-06-ATRTQ54812146
CHLA-07-BSGBMQ54812147
CHLA-259Q54812495
D283 MedQ54817202
D425 MedQ54817229
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectbrain tumorQ233309
cell lineQ21014462
P304page(s)827-836
P577publication date2013-12-03
P1433published inClinical Cancer ResearchQ332253
P1476titlePID1 (NYGGF4), a new growth-inhibitory gene in embryonal brain tumors and gliomas
P478volume20

Reverse relations

described by source (P1343)
Q54812135CHLA-01-MED
Q54812137CHLA-01R-MED
Q54812145CHLA-05-ATRT
Q54812146CHLA-06-ATRT
Q54812147CHLA-07-BSGBM
Q54812495CHLA-259
Q54817202D283 Med
Q54817229D425 Med

cites work (P2860)
Q35550199Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target.
Q35999183Disseminated Medulloblastoma in a Child with Germline BRCA2 6174delT Mutation and without Fanconi Anemia
Q39480138Inhibition of PID1/NYGGF4/PCLI1 gene expression highlights its role in the early events of the cell cycle in NIH3T3 fibroblasts.
Q42330162Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia
Q33678251PID1 increases chemotherapy-induced apoptosis in medulloblastoma and glioblastoma cells in a manner that involves NFκB.
Q38957473Pediatric brain tumor cell lines
Q42369040The Effect of Different Case Definitions of Current Smoking on the Discovery of Smoking-Related Blood Gene Expression Signatures in Chronic Obstructive Pulmonary Disease
Q52092512The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity.
Q36416243The chromatin-modifying protein HMGA2 promotes atypical teratoid/rhabdoid cell tumorigenicity
Q91838867Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine
Q35788801Wnt pathway in atypical teratoid rhabdoid tumors

Search more.